RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
RedHill Biopharma (RDHL) is actively discussing collaborations to advance its investigational drug opaganib for the current Ebola virus disease outbreak, including with the WHO's SOLIDARITY CORE platform. The company cites opaganib's 70.2% mortality reduction in severe COVID-19 trials and preclinical data showing inhibition of EVD and synergistic effects with direct-acting antivirals like remdesivir. Cumberland Pharmaceuticals (CPIX) is mentioned as the U.S.
Key figures
- Drug Name
- opaganib
- Clinical participants
- 470
- Mortality reduction covid
- 70.2%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.